The advance of immunotherapy across the field of oncology in recent years has been remarkable, but a mechanistic understand ing of the antitumour immune responseespecially within the tumour micro environment -remains in its relative infancy. Furthermore, although the breadth of responses across multiple tumour types has been noted, the fact that a minority of patients have objective responses to immune based therapies is often overlooked. A recent publication by Gao and colleagues 1 in Nature Medicine provides a detailed analysis of the immunological effects of ipilimumab in patients with prostate cancer, suggesting upregulation of the immune checkpoints programmed cell death ligand 1 (PDL1) and Vtype immunoglobulin domaincontaining suppressor of Tcell activation (VISTA). These findings might provide guidance on how immunebased therapies can be optimized in patients with advanced solid tumours.
Prostate cancer presents a perplexing immunotherapeutic dilemma. A therapeutic cancer vaccine, sipuleucelT, demonstrated an overall survival advantage in a phase III trial and an ability to mobilize immune cells to the tumour microenvironment in the neoadjuvant setting 2, 3 . By contrast, immune checkpoint inhibitors (antiPD1 or antiPDL1 anti bodies) have demonstrated modest success in small cohorts or -in the case of ipilimumab, antitumour response. A broader analysis suggested that these findings were independent of androgen deprivation therapy (a standard of care for patients with prostate cancer) and con sistent regardless of whether the patients had localized or metastatic disease.
In conjunction with the reported immune response in the tumour microenvironment, upregulation of PDL1 was also observed. This upregulation could be predicted, based on previous data suggesting that immune infiltration of the tumour microenvironment might be accompanied by increased PDL1 expression, leading to neutralization of the antitumour immune effect 7 . This mechanism could explain why the combination of ipili mumab and nivolumab has demonstrated greater efficacy in melanoma than ipilimumab alone 8 . Particularly provocative in the current study was the increased expression of a second immune checkpoint in the tumour micro environment, VISTA, which is predominantly expressed on cells of a myeloid lineage 9 .
CD68
+ macrophages nearly doubled in the tumour after treatment with ipili mumab from a median of ~20% to ~35% (P = 0.0001), and many of them expressed PDL1 (29.4%) or VISTA (26.5%) 1 . Notably, only 2% of the CD68 + cells expressed both PDL1 and VISTA. These data highlight the complex biology of an antitumour immune response that has multiple compensatory hurdles to overcome before clinically rel evant responses could be observed. These data also suggest that altered expression an antiCTLA4 therapy -no success in two phase III trials [4] [5] [6] . Nonetheless, in a study of patients with prostate cancer, Gao and col leagues report increased tumour infiltration with CD4 + and CD8 + T cells after treatment with ipilimumab, similar to that observed in bladder cancer and melanoma, in which this treatment has a better clinical track record 1 . Markers consistent with the presence of nat ural killer cells (granzyme B), macrophages (CD68 + ), and memory T cells (CD45RO + ) were also increased in the tumours, suggesting a multilineage
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of VISTA could be an important immuno regulatory mechanism in prostate cancer. This analysis could also inform the clinical findings of the phase III study in chemotherapynaive, metastatic castration resistant prostate cancer that evaluated ipil imumab versus placebo 4 . The study did not yield an overall survival benefit, but it did demonstrate a progressionfree survival advan tage favouring ipilimumab (median 5.6 months versus 3.8 months, HR 0.67). Although toxicity might have been a mitigating factor affecting longterm outcomes, could the shortterm clinical benefit have been overcome by com pensatory immune mechanisms of regulation such as VISTApositive macrophages?
The effect of VISTA on the outcomes of past clinical trials in prostate cancer can not be ascertained, but the report from Gao and colleagues 1 has important implications for future studies. Firstly, and perhaps most importantly, these findings give a pause to the assumption that tumours that do not respond to PD1 and/or PDL1 inhibition are not immune responsive -on the contrary, they might be responsive, but PD1 and PDL1 might not be the only relevant or sufficient targets. Secondly, and from a broader perspective, these data highlight the need for immunotherapy to be deployed as multi faceted platforms that can both mobi lize immune cells to the tumour micro environment (as is the case for ipilimumab and therapeutic vaccines) and then keep such cells functional once they get there (the role of microenvironment checkpoint inhibitors).
Perhaps the most important upshot of this study is that those working in the immunotherapy field must evaluate the effect of immunotherapies within the tumour microenvironment, in order to identify potentially relevant counter regulatory or resistance mechanisms. The tumour microenvironment could present an immunological 'whackamole' of sorts, whereby rolling mechanisms of immune compensation result in (possibly sequential) upregulation of multiple regula tory immune checkpoints that could hinder clinical benefit, even if the underlying immunebased therapy (in this case, ipili mumab) is effective at increasing immune recognition and mobilizing these cells to the tumour. Furthermore, emerging data suggest that, even within each patient, a heterogeneous immunological milieu might exist that differs from lesion to lesion within the same patient 10 . In this context, perhaps certain other checkpoints are more rele vant in specific bone, lymph node, or vis ceral tumour microenvironments. Further studies, similar to that carried out by Gao and colleagues 1 , will be required to fully understand these points.
Gao and colleagues' paper 1 illustrates how far the field has progressed in a few short years, but also highlights how much remains undiscovered. Ipilimumab, despite failed phase III trials, is shown to mobilize immune cells to the tumour; regulatory mechanisms blunting its potential anti tumour effects can be identified and tar geted -antiVISTA agents are in clinical development. However, important questions remain, including the ubiquity of VISTA expression across all men with prostate can cer and among patients with other cancers. Furthermore, whether any immunebased therapy that mobilizes T cells can induce VISTA expression as a regulatory mech anism, or whether this effect is specific to ipilimumabbased immune mobilization remains to be elucidated.
Finally, studies like this report from Gao et al. 1 highlight the fact that clinical development of immunotherapy needs to move quickly into the combination phase. Although limited studies currently combine more than just one or two of these agents, these data illustrate the potential futility and missed opportunities when these agents are evaluated as single agents. Medical on cology might finally have the therapeutic tools to match the heterogeneity of cancer but, as these data show, we must not be shy in deploying them together in order to overcome this disease.
